Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30238% above fair value
$4.59−0.09 (-1.89%)
Close on Nov 17, 2026Market cap $63.91MP/E –Yield –
Champions Oncology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Champions Oncology's operating income for the twelve months ending Jul 31, 2026 was -$1.02M, down 137.9% year over year. For fiscal 2026 it was -$1.14M, down 125.0% from the year before. The highest annual figure on record is $4.55M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | -$1.14M | -125.0% |
| FY2025 | Apr 30, 2025 | $4.55M | – |
| FY2024 | Apr 30, 2024 | -$7.36M | – |
| FY2023 | Apr 30, 2023 | -$5.26M | -965.9% |
| FY2022 | Apr 30, 2022 | $607.00K | +65.8% |
| FY2021 | Apr 30, 2021 | $366.00K | – |
| FY2020 | Apr 30, 2020 | -$1.92M | -811.5% |
| FY2019 | Apr 30, 2019 | $270.00K | – |
| FY2018 | Apr 30, 2018 | -$1.35M | – |
| FY2017 | Apr 30, 2017 | -$6.81M | – |
| FY2016 | Apr 30, 2016 | -$10.32M | – |
| FY2015 | Apr 30, 2015 | -$13.24M | – |
| FY2014 | Apr 30, 2014 | -$6.26M | – |
| FY2013 | Apr 30, 2013 | -$6.22M | – |
| FY2012 | Apr 30, 2012 | -$9.07M | – |
| FY2011 | Apr 30, 2011 | -$5.24M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | -$409.00K | – |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | -$522.00K | – |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | -$276.00K | -106.1% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | $185.00K | -74.7% |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | -$527.00K | -139.7% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | -$2.01M | – |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | $4.50M | – |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | $732.00K | – |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $1.33M | – |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | -$271.00K | – |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | -$2.58M | – |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | -$1.96M | -28028.6% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | -$2.55M | – |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | -$2.52M | – |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | -$2.46M | -396.1% |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | $7.00K | -97.3% |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | -$284.00K | – |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | -$311.00K | – |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | $830.00K | -15.5% |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | $263.00K | +3657.1% |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | -$175.00K | -829.2% |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | -$648.00K | – |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | $982.00K | +126.8% |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | $7.00K | -97.6% |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | $24.00K | – |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | -$2.03M | – |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | $433.00K | – |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | $291.00K | +5.8% |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | -$614.00K | -227.7% |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | -$116.00K | – |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | -$370.00K | – |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | $275.00K | – |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | $481.00K | – |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | -$599.00K | – |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | -$67.00K | – |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | -$70.00K | – |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | -$619.00K | – |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | -$2.39M | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | -$1.40M | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | -$493.00K | – |
See a number that looks wrong?